An adhesion barrier describes a medical implant that can be utilized to reduce abnormal internal scarring by adhesions following any surgery by segregating the internal tissues and organs as long as they cure. According to BlueQuark's, the Global Adhesion Barrier Market is expected to witness a considerable growth rate during the forecast period. Factors such as the surging number of surgical procedures due to sports injuries, accidents, and orthopaedic surgeries are predicted to drive the Adhesion Barrier Market in the forecasted period. Further, growing awareness about adhesion formation and adhesion-related diseases among patients and healthcare professionals is expected to drive the Adhesion Barrier Market in the forecasted period. However, the high cost of surgical procedures coupled with side effects associated with adhesion barriers and stringent regulations resulting in fewer technological innovations are expected to restrain the growth of the adhesion barrier market.

The Gynecological Surgeries segment is awaited to have the largest share of the market and is poised to dominate the market in the forecasted period. The number of gynecologic laparoscopy procedures, pelvic surgeries, ovarian cystectomies, and laparotomy procedures increased. Adhesion barriers help decrease the risk of developing clinically significant adhesions, especially among patients with endometriosis/pelvic inflammatory disease or undergoing a myomectomy. Adhesion barriers are being used more frequently as surgical procedures multiply. The sterile, clear, and highly dense adhesion barriers in gel form serve as a barrier to stop or lessen post-surgical adhesions at the surgical site. One example of a gel formulation that is sold commercially is hyalobarrier gel. The internal tissue surfaces of the organ and the adhesion barrier are often prevented from adhering to one another during and after surgery by the liquid form of the adhesion barrier, typically made of high molecular glucose polymers, such as Icodextrin. The adhesive disease represents a significant cause of morbidity for postoperative patients. Adhesion barriers have been proven to reduce adhesion-related complications in gynaecological surgery. The use of adhesion barriers in open surgery is cost-effective in preventing adhesion-related problems. Adhesion formation after gynaecologic surgeries is widespread and highly problematic as it directly induces complications and makes subsequent surgeries more difficult. Adhesion barriers to overcoming this problem have proven safe and effective. Adhesion barriers help in significantly reducing both adhesion extent and severity in comparison to untreated control. The increasing incidence of heart-related diseases and the growing use of adhesion barriers in cardiovascular surgeries are the significant drivers of growth in this advanced adhesion barrier market segment. Further, increasing the adoption of gel form and film form in various gynaecological procedures, including endometriosis surgery, ovarian cystectomy, and ectopic pregnancy, is advancing the market growth. Slow adoption of minimally invasive techniques is expected to impact adhesion barriers adoption. Minimally invasive surgeries require high-priced equipment such as cameras and robot-assisted devices. Adoption of these devices is predicted to be moderate in developing countries due to price-sensitive customers. Thus, the fragment is expected to witness significant development in the forecasted period due to the abovementioned factors, such as increasing gynaecological surgeries and increasing advantages of adhesion barriers in gynaecological surgeries.

North America is driven by technological advancement, elderly patients predicting higher levels of function, and reimbursement models incentivizing complex fusion surgery. Adhesion barriers are also valuable for oncology surgeries. Furthermore, growing awareness among the population to approach surgical procedures in case of injuries and chronic disease problems is also driving market growth. Synthetic adhesion barriers are cost-effective, which is projected to increase segment sales. Moreover, the segment's dominance is primarily attributed to the availability of commercial artificial adhesion barriers. The segment is divided into hyaluronic acid, regenerated cellulose, polyethene glycol, and others. The hyaluronic acid segment dominates due to its capacity to attract and hold much moisture. The collagen & protein segment had the largest market size due to its benefits, such as durability and safety. The fibrin segment is expected to increase during the forecast period. The high growth rate of the fibrin fragment is primarily attributed to the escalating adoption of these products. Growing investments in technological advancements are awaited to increase the need for adhesion barriers. Biological adhesive biomaterials are being improved in orthopaedic applications due to the rapid acceleration of technical progress. Some examples of recently made bioadhesive materials include polymers that can be sprayed on interior wounds to produce a seal against tissue and halt bleeding across broad areas. Numerous scientific publications show that osteochondral fractures, chondral fractures, and soft tissue in the musculoskeletal system have a surge in beneficial biological adhesive components. Growing female infertility globally is another factor fueling market revenue growth. Gynaecologists routinely employ fencing gel after surgical hysteroscopy in infertile women to minimize the formation of De Novo Adhesions. Preclinical research recommends that using biodegradable surgical barriers could decrease the growth of post-surgical adhesions. Thus, with increasing numbers of global female infertility, there is an expected growing demand for adhesion barriers.

The market players are Sanofi S.A., Baxter International, Inc., Becton Dickinson and Company, Johnson & Johnson, and Anika Therapeutic, Inc.

In June 2022, the bio-regenerative medicine business CGBIO launched the Indonesian market with MEDICLORE, a fourth-generation sol-gel type anti-adhesion agent. When MEDICLORE is operated on the body, it transforms from a sol state at ambient temperature to a highly dense gel state at body temperature. This gel-like state is a physical barrier in the surgical site to preserve adhesion as the wound heals.

In February 2022, Gunze Limited, the company, assumed that TENALEAF, the first sheet type absorbable adhesion barrier produced in Japan, had obtained medical device approval. The company plans to enter the gadget in the Japanese market in March 2022 through its affiliate, Gunze Medical Japan. Gunze developed its absorbable adhesion barrier using cutting-edge absorbable material technology to provide a ground-breaking solution in this industry.

Global Adhesion Barrier Market report provides deep insight into the Industrial market's current and future state across various regions. The study comprehensively analyses the Adhesion Barrier market by segmenting based on the Product (Synthetic Adhesion Barriers (Hyaluronic Acid, Regenerated Cellulose, Polyethylene Glycol, and Other Synthetic Adhesion Barriers) and Natural Adhesion Barriers (Collagen and Fibrin)), Formulation (Film, Liquid, and Gel), Application (General/Abdominal Surgeries, Gynecological Surgeries, Cardiovascular Surgeries, Orthopedic Surgeries, Neurological Surgeries, and Other Applications), and Geography (Asia-Pacific, North America, Europe, South America, and Middle-East and Africa). The report examines the market drivers and restraints and the impact of Covid-19 on market growth in detail. The study covers emerging market trends, market share, market analysis, developments, opportunities, and challenges in the industry. The report also covers extensively researched competitive landscape sections with prominent companies and profiles, including their market shares and projects.